

# Anti-SOST (Romosozumab), Humanized Antibody

09/20

---

**CATALOG NO.:** A2219-100 (100 µg)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a humanized IgG2 monoclonal antibody that specifically targets Sclerostin (SOST). Sclerostin is a glycoprotein secreted by the osteocytes during the remodeling of the bone. It binds to LRP5/6, a Wnt co-receptor, inhibits Wnt signaling pathway and bone formation. The antibody binds to and inhibits Sclerostin, thus releasing the inhibitory effect on Wnt signaling and enabling bone formation. The original antibody was approved by the FDA to treat postmenopausal women with osteoarthritis and patients that are at a high risk of fracture or have failed therapy for osteoporosis.

**ALTERNATE NAMES:** CDD, VBCH, DAND6, SOST1, Sclerostin, SOST, Sclerosteosis, AMG 785, CDP 7851, 785A070802

**ANTIBODY TYPE:** Monoclonal

**HOST/ISOTYPE:** Recombinant / IgG2, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human SOST

**CAS NUMBER:** 909395-70-6

**MOLECULAR WEIGHT:** 145.805 kDa

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-TNFSF11 (Denosumab), Human IgG2 Antibody (A2150)

Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)

Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)

Anti-TNSF13B (Belimumab), Human IgG1 Antibody (A2170)

**FOR RESEARCH USE ONLY! Not to be used on humans.**